Pembrolizumab for Advanced Urothelial Carcinoma

被引：49
作者：
Liang, Fei [1 ]
Zhu, Ji [1 ]
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2017年 / 376卷 / 23期
关键词：
D O I：
10.1056/NEJMc1704612
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2302 / 2302
页数：1
相关论文
共 2 条
  • [1] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
    Bellmunt, J.
    de Wit, R.
    Vaughn, D. J.
    Fradet, Y.
    Lee, J. -L.
    Fong, L.
    Vogelzang, N. J.
    Climent, M. A.
    Petrylak, D. P.
    Choueiri, T. K.
    Necchi, A.
    Gerritsen, W.
    Gurney, H.
    Quinn, D. I.
    Culine, S.
    Sternberg, C. N.
    Mai, Y.
    Poehlein, C. H.
    Perini, R. F.
    Bajorin, D. F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) : 1015 - 1026
  • [2] Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
    Plimack, Elizabeth R.
    Bellmunt, Joaquim
    Gupta, Shilpa
    Berger, Raanan
    Chow, Laura Q. M.
    Juco, Jonathan
    Lunceford, Jared
    Saraf, Sanatan
    Perini, Rodolfo F.
    O'Donnell, Peter H.
    [J]. LANCET ONCOLOGY, 2017, 18 (02) : 212 - 220
1